Merck & Co., Inc. (NYSE:MRK) Position Reduced by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. lowered its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,058 shares of the company’s stock after selling 137 shares during the period. YHB Investment Advisors Inc.’s holdings in Merck & Co., Inc. were worth $1,099,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. E&G Advisors LP raised its position in shares of Merck & Co., Inc. by 0.7% during the second quarter. E&G Advisors LP now owns 16,378 shares of the company’s stock valued at $1,493,000 after buying an additional 110 shares during the last quarter. Paulson Wealth Management Inc. raised its position in Merck & Co., Inc. by 1.9% in the first quarter. Paulson Wealth Management Inc. now owns 6,144 shares of the company’s stock worth $504,000 after purchasing an additional 115 shares in the last quarter. Private Management Group Inc. raised its position in Merck & Co., Inc. by 0.4% in the first quarter. Private Management Group Inc. now owns 28,832 shares of the company’s stock worth $2,366,000 after purchasing an additional 117 shares in the last quarter. Disciplined Investments LLC raised its position in Merck & Co., Inc. by 24.3% in the first quarter. Disciplined Investments LLC now owns 604 shares of the company’s stock worth $50,000 after purchasing an additional 118 shares in the last quarter. Finally, Pegasus Asset Management Inc. raised its position in Merck & Co., Inc. by 0.3% in the first quarter. Pegasus Asset Management Inc. now owns 34,987 shares of the company’s stock worth $2,871,000 after purchasing an additional 119 shares in the last quarter. Institutional investors own 73.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MRK shares. UBS Group upped their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a research note on Monday, July 18th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $100.00 in a research note on Wednesday, September 14th. SVB Leerink raised their price objective on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research note on Monday, September 12th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, June 24th. They issued a “buy” rating and a $100.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a report on Friday, July 29th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $98.28.

Merck & Co., Inc. Trading Up 3.5 %

NYSE:MRK opened at $87.51 on Friday. The firm’s fifty day moving average is $88.83 and its 200-day moving average is $87.81. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39. Merck & Co., Inc. has a 52 week low of $71.50 and a 52 week high of $95.72. The firm has a market cap of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue was up 28.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.31 earnings per share. Equities analysts expect that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a $0.69 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 annualized dividend and a dividend yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.